SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently trending as the community debates the success of the Starship Flight 13 test launch, with investors divided between bullish excitement over its technological achievements and bearish concerns regarding the company's valuation and upcoming share lock-up expirations. Market participants are actively discussing the stock's volatility, focusing on whether the successful deployment of Starlink satellites and mission milestones will trigger a short squeeze or if the shares face further downward pressure.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased social media attention as investors debate its long-term potential, with bulls pointing to enterprise-grade integrations and quantum-secure technology while bears remain skeptical of its price action. Many community members are actively discussing the possibility of a momentum shift as they continue to accumulate positions at current support levels.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance Corp. (PSKY) is trending as the community debates a multi-state antitrust lawsuit aiming to block its massive merger with Warner Bros. Discovery. While some investors fear the legal uncertainty and potential ticking fees will lead to a collapse or bankruptcy, others view the current price drop as a generational buying opportunity, arguing the legal challenges are politically motivated and that the merger remains essential for long-term industry competitiveness.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as investors react to a favorable FDA advisory committee recommendation for certain peptides, triggering a sharp rally and significant short-covering activity. The community is actively debating the stock's long-term growth potential in the wellness and longevity market while monitoring volatile price action and heavy short interest.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following a significant sell-off triggered by a negative opinion from the EMA's CHMP regarding the marketing authorization application for arimoclomol, with the company planning to request a formal re-examination. While the community is debating the impact of this setback on the company's valuation and the reliability of current management, many investors are highlighting the stock's continued U.S. revenue growth and strong cash position as reasons to view the price decline as an overreaction.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending as investors react to a significant workforce reduction of over 1,100 employees, which the company frames as a strategic shift toward an agentic AI-first operating model. Community discussion is heavily focused on balancing this aggressive move toward AI-driven efficiency against short-term margin pressures and the company's high valuation multiples.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing extreme volatility and intense selling pressure as investors scrutinize the company's aggressive debt-fueled AI infrastructure build-out and ongoing share dilution. Despite recently landing a major government contract, community sentiment remains deeply divided between those citing oversold conditions and strong long-term fundamentals and those fearing systemic risks, poor leadership, and the potential for a deeper correction.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending due to a sharp sell-off following a strong earnings report, as investors remain divided over the company's aggressive increase in capital expenditure for AI infrastructure. The community is actively debating whether this decline represents a manipulative stop-loss raid by institutional market makers or a justified reaction to valuation concerns and macro pressures impacting the broader semiconductor sector.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is surging following a strong quarterly earnings report that highlighted accelerating AI-driven demand and increased enterprise adoption, helping to silence broader market concerns about software stocks. The community is actively discussing the stock's role as a mission-critical AI infrastructure play, with many investors debating whether the current momentum validates a long-term re-rating or warns of an overextended valuation.

Direxion Shares ETF Trust - Direxion Daily TSLA Bull 2X ETF

Direxion Daily TSLA Bull 2X Shares

TSLL is drawing significant attention as investors react to volatility in the underlying Tesla stock, with many in the community debating whether current price levels represent a bottom-fishing opportunity or a value trap. Discussion is focused on using leveraged ETFs as a strategic tool for short-term swings, with many traders actively managing risk through covered calls and hedging techniques to navigate ongoing market uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$AMRN I noticed there are only 20 people registered for Dr Bhatt’s talk this afternoon and 2 of them are “employees of AMGEN” hmmm. Both are “Medical Science Liason”. Why is Amgen so interested in Amarin’s drug being effective for treating Covid??????

LJOHN484

1of789

Sieppo

Jay G

Steve Rodgers

ONCEINALIFETIME

Michael Henderson

jay spinelli

Iryokabu

Steve Rogers

Anil

Who_is_JohnnyGalt

ShortFishFry

sanam

Kishore Rachamalla

Bruce Lee

Amit Khatkar

StockTwits for iOS

Amarin Corp - ADR

 I noticed there are only 20 people registered for Dr Bhatt’s talk this afternoon and 2 of them are “employees of AMGEN” hmmm. Both are “Medical Science Liason”. Why is Amgen so interested in Amarin’s drug being effective for treating Covid??????

Mark Brady

@Pharmacydude can we see that info too? Is that a low number?

 can we see that info too? Is that a low number?

@Gaar https://nlasessions.pathable.co/meetings/PAfjHhtXbyGSwiycS#/?limit=10&amp;sortByFields[0]=isPinned&amp;sortByFields[1]=lastActivityAt&amp;sortByOrders[0]=-1&amp;sortByOrders[1]=-1&amp;uid=peTero2J6SWhrB5Cb

Pathable

@Pharmacydude 20 seems like a pretty light number?

Sweaty Tricks

@Pharmacydude Lets be real ... they could be there for the free pens and stress balls they give out.

Bill

edward

StockTwits For Android 

 Lets be real ... they could be there for the free pens and stress balls they give out.

Rai Den

@VascepaBID It’s a virtual conference. They don’t get anything

 It’s a virtual conference. They don’t get anything

@Pharmacydude @Gaar 20 is too low.. can’t read too much into attending 2 people being from same company

 20 is too low.. can’t read too much into attending 2 people being from same company

Brad

@Bradicelandic @Gaar perfect comarketing product for Repatha. Amgen has a great PCSK9 to lower LDL and there revenue is falling hard lately so they desperately need a new blockbuster

morisboris

Kim Frazier

 perfect comarketing product for Repatha. Amgen has a great PCSK9 to lower LDL and there revenue is falling hard lately so they desperately need a new blockbuster

@Pharmacydude Wondering if they need a replacement for heart drug medicine.  In November they ended collaboration with Cytokinetics.

 Wondering if they need a replacement for heart drug medicine.  In November they ended collaboration with Cytokinetics.

Buy the fear!

@Pharmacydude @Gaar every BP has a product which can be matched with Vascepa . I’m not trying to undermine the great work you are doing , it’s just that we can’t read too much . I would be glad if Amgen buys , thanks for all your dd .

 every BP has a product which can be matched with Vascepa . I’m not trying to undermine the great work you are doing , it’s just that we can’t read too much . I would be glad if Amgen buys , thanks for all your dd .

@Bradicelandic @Gaar Sorry!!!! Everyone. False alarm. There are 3 trials. 2 are EPA and one is inclisiran (a competitor of Amgen’s Repatha). The 2 Amgen people are registered for all 3 presentations and are likely just there to check out their competition. $AMRN

 Sorry!!!! Everyone. False alarm. There are 3 trials. 2 are EPA and one is inclisiran (a competitor of Amgen’s Repatha). The 2 Amgen people are registered for all 3 presentations and are likely just there to check out their competition. 

@Pharmacydude they need drug portfolio help by the way....they are actively looking for companies to acquire one rumor was $srne Sorrento Pharmaceuticals as well. They are way behind the eightball for covid.

Sorrento Therapeutics Inc

 they need drug portfolio help by the way....they are actively looking for companies to acquire one rumor was 

 Sorrento Pharmaceuticals as well. They are way behind the eightball for covid.